Friday, 17 Aug 2018

You are here

Risk of Paternal Exposure to Anti-Rheumatic Drugs

Seminars in Arthritis and Rheumatism features a review of the effects of paternal use of antirheumatic drugs on pregnancy, specifically addressing the effects of NSAIDs, steroids, DMARDs and biologics on spermatogenesis and the effect on pregnancy outcomes and offspring.

There is limited data regarding paternal exposure to arthritis medications, and less counseling of would-be fathers about the fetal effects of their medications.  This review discusses the approach and provides a compendium of data in text and table form on what is currently known, as digested by authorities in this area. 

There are several take-home messages from this report:

1. Many of our current limitations are due to a lack of robust data regarding paternal exposure with individual drugs.

2. Many antirheumatic medications can be continued in men who want to father a child.

3. Regular pre-conceptional counseling should be given to male patients of fertile age as an integral part of family planning.

4. It is erroneous to extrapolate from the female pregnancy experience when counseling their male partners.

Examples of drug effect on Spermatogenesis and Counseling Recommendations include:  

DrugSpermatogenesisMale Counseling
NSAIDSNot fully investigated no link between paternal drug exposure and adverse pregnancy outcomes
SteroidsLimited data; no correlation with infertility in menNo harmful effects have emerged for low (<10 mg prednisone/day) doses.
MTXStudies showed alterations in sperm DNA after MTX exposure Some believe it is ok to maintain MTX therapy in men throughout the disease course to avoid unnecessary flares, as controlled studies have not shown increased malformation rates with male exposure
SSZOligospermia, reduced mobility and increase of pathologic sperm morphology Stop SSZ 3 months before conception 
MMFLimited data; but no effect on sperm in rat studies MMF is a known, clear teratogen in women. But 3 studies in men have failed to show any increase risk of malformations with male use of MMF.
AZANo impairment No increased risk of congenital abnormalities in offspring of fathers treated with thiopurines and male fertility not affected
 TNF inhibitors No impairment TNFi do not influence male fertility or harm offspring. Risks are the same as female exposure and thus should be continued to avoid flare (if needed)
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).